New rabies vaccine passes first safety check in small trial
NCT ID NCT06132789
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new rabies vaccine in 80 healthy people aged 10 to 60. Participants received one of two different vaccination schedules. Researchers monitored for side effects for up to 6 months. The goal was to see if the vaccine is safe enough to move to larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rabies vaccine (human diploid cell), freeze-dried
- What this could lead to
- If successful, this could confirm a safe way to give a new rabies vaccine, potentially improving rabies prevention.
- What could go wrong
- This is a very early Phase 1 safety trial with only 80 participants. It cannot prove the vaccine works, only that it is safe enough to test further.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gucheng Center for Disease Control and Prevention
Xiangyang, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental antibody cocktail offers hope for rabies patients with no other options
- New antibody cocktail aims to stop rabies after multiple dog bites
- New vaccines for yellow fever and rabies enter first human tests
- New rabies vaccine shows promise in large trial
- Could a tiny skin shot replace the big rabies needle?
- New rabies shot shows promise in preventing deadly infection after bites